CN101932594A - 可用作疫苗的自装配肽纳米颗粒 - Google Patents
可用作疫苗的自装配肽纳米颗粒 Download PDFInfo
- Publication number
- CN101932594A CN101932594A CN2009801037674A CN200980103767A CN101932594A CN 101932594 A CN101932594 A CN 101932594A CN 2009801037674 A CN2009801037674 A CN 2009801037674A CN 200980103767 A CN200980103767 A CN 200980103767A CN 101932594 A CN101932594 A CN 101932594A
- Authority
- CN
- China
- Prior art keywords
- peptide
- cell epitope
- coiled
- composition
- coil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08101221 | 2008-02-01 | ||
| EP08101221.3 | 2008-02-01 | ||
| PCT/EP2009/050996 WO2009109428A2 (en) | 2008-02-01 | 2009-01-29 | Self-assembling peptide nanoparticles useful as vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101932594A true CN101932594A (zh) | 2010-12-29 |
Family
ID=39276265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801037674A Pending CN101932594A (zh) | 2008-02-01 | 2009-01-29 | 可用作疫苗的自装配肽纳米颗粒 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8546337B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2235043A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6088123B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101932594A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009221419B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2713879C (cg-RX-API-DMAC7.html) |
| RU (1) | RU2540871C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009109428A2 (cg-RX-API-DMAC7.html) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104011065A (zh) * | 2011-08-23 | 2014-08-27 | 哈佛大学校长及研究员协会 | 肽纳米粒子及其用途 |
| CN104136454A (zh) * | 2011-10-12 | 2014-11-05 | 阿尔法-O肽股份公司 | 作为针对诺如病毒感染的疫苗的自装配肽纳米粒 |
| CN105960412A (zh) * | 2014-01-09 | 2016-09-21 | 阿尔法欧多肽股份公司 | 作为疫苗平台的含鞭毛蛋白的蛋白纳米颗粒 |
| CN110290805A (zh) * | 2017-01-03 | 2019-09-27 | 埃默杰克斯疫苗控股有限公司 | 通用流感疫苗组合物 |
| CN110996995A (zh) * | 2017-03-23 | 2020-04-10 | 阿尔法-O肽股份公司 | 具有内置六螺旋束蛋白的自组装蛋白纳米粒子 |
| CN111150841A (zh) * | 2019-12-31 | 2020-05-15 | 优锐生物医药科技(深圳)有限公司 | 一种主动免疫调控微粒及其制备方法和应用 |
| CN111150842A (zh) * | 2019-12-31 | 2020-05-15 | 优锐生物医药科技(深圳)有限公司 | 一种用于中和胃泌素的主动免疫调控微粒及其制备方法和应用 |
| CN111333733A (zh) * | 2019-04-29 | 2020-06-26 | 中国人民解放军军事科学院军事医学研究院 | 一种可自组装为蛋白纳米颗粒的融合蛋白及其应用 |
| CN119060144A (zh) * | 2024-10-31 | 2024-12-03 | 南京澄实生物医药科技有限公司 | 一种预防犬瘟热病毒感染的融合蛋白和疫苗及其应用 |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
| WO2008105773A2 (en) | 2006-03-31 | 2008-09-04 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
| US8367113B2 (en) | 2006-05-15 | 2013-02-05 | Massachusetts Institute Of Technology | Polymers for functional particles |
| WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
| US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
| US20090074828A1 (en) | 2007-04-04 | 2009-03-19 | Massachusetts Institute Of Technology | Poly(amino acid) targeting moieties |
| MX2010003642A (es) | 2007-10-12 | 2010-08-09 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
| US20120015000A1 (en) * | 2008-06-30 | 2012-01-19 | David Lanar | Malaria vaccine of self-assembling polypeptide nanoparticles |
| US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| KR101329374B1 (ko) * | 2008-12-09 | 2013-11-14 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 면역자극성 올리고뉴클레오타이드 |
| JP5557254B2 (ja) * | 2009-02-10 | 2014-07-23 | 国立大学法人 琉球大学 | 薬物運搬体並びにこれを利用したアジュバントおよびワクチン |
| WO2010138193A2 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
| CN107617110A (zh) * | 2009-08-26 | 2018-01-23 | 西莱克塔生物科技公司 | 诱导t细胞辅助的组合物 |
| CN102939101A (zh) * | 2010-01-26 | 2013-02-20 | 科罗拉多大学董事会,法人 | 用于通用疫苗的流感病毒组合物和方法 |
| CN107029223A (zh) * | 2010-05-26 | 2017-08-11 | 西莱克塔生物科技公司 | 合成纳米载体联合疫苗 |
| EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
| CA2833425C (en) * | 2011-04-07 | 2018-08-21 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Protease cleavage site peptides as an hiv vaccine |
| JP2014521687A (ja) | 2011-07-29 | 2014-08-28 | セレクタ バイオサイエンシーズ インコーポレーテッド | 体液性および細胞傷害性tリンパ球(ctl)免疫応答を生成する合成ナノキャリア |
| SI23902A (sl) * | 2011-10-07 | 2013-04-30 | Kemijski inštitut | Samosestavljivi polipeptidni poliedri |
| US9550813B2 (en) | 2012-05-22 | 2017-01-24 | The Board Of Trustees Of The Leland Stanford Junior University | Disulfide stabilized foldon polypeptides |
| JP2015519348A (ja) * | 2012-05-23 | 2015-07-09 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | インフルエンザワクチン構築物 |
| EP2703483A1 (en) * | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
| KR20150085843A (ko) | 2012-11-20 | 2015-07-24 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Rsv f 융합전 삼합체 |
| US10248758B2 (en) * | 2013-02-07 | 2019-04-02 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
| WO2015035010A1 (en) * | 2013-09-05 | 2015-03-12 | Immune Design Corp. | Vaccine compositions for drug addiction |
| CN104513293A (zh) * | 2013-09-26 | 2015-04-15 | 深圳信立泰药业股份有限公司 | 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品 |
| EP3054971B1 (en) | 2013-10-11 | 2021-03-10 | The United States of America, represented by the Secretary, Department of Health and Human Services | Epstein-barr virus vaccines |
| US10111948B2 (en) | 2014-04-25 | 2018-10-30 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
| EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
| BR112017014219A2 (en) | 2014-12-31 | 2018-03-06 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | multivalent nanoparticle-based vaccines |
| WO2016122414A1 (en) * | 2015-01-29 | 2016-08-04 | Agency For Science, Technology And Research | Nanocapsules carrying chikungunya-associated peptides |
| WO2016138525A1 (en) | 2015-02-27 | 2016-09-01 | University Of Washington | Polypeptide assemblies and methods for the production thereof |
| US9850288B2 (en) | 2015-03-16 | 2017-12-26 | The Catholic University Of America | Method of purifying authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag |
| WO2016207782A1 (en) * | 2015-06-22 | 2016-12-29 | STRELNIKOV, Evgeny | Immunogenic synthetic oligopeptides for a vaccine against hiv |
| CN105409831A (zh) * | 2015-10-30 | 2016-03-23 | 河南科技学院 | 一种利用ghrelin减少新生雏鸡脂肪细胞分化和降低脂肪沉积的方法及应用 |
| CN105210995A (zh) * | 2015-10-30 | 2016-01-06 | 河南科技学院 | 一种利用ghrelin促进新生雏鸡免疫器官发育的方法及应用 |
| CN105393976A (zh) * | 2015-10-30 | 2016-03-16 | 河南科技学院 | 一种利用ghrelin促进新生雏鸡生长性能的方法及应用 |
| US10188136B2 (en) | 2016-02-16 | 2019-01-29 | Indian Institute Of Science Education And Research | Hydrophobin mimics: process for preparation thereof |
| FR3050448A1 (fr) * | 2016-04-21 | 2017-10-27 | Bioaster | Nanoparticules a base d'encapsuline. |
| CN109153704A (zh) | 2016-05-02 | 2019-01-04 | 斯克里普斯研究学院 | 与hiv-1免疫原相关的组合物和方法 |
| CN110167585B (zh) | 2016-09-02 | 2024-03-08 | 美国卫生与公众服务部 | 稳定化的第2组流感血凝素茎区三聚体及其用途 |
| EP3585428A1 (en) | 2017-02-23 | 2020-01-01 | Alpha-o Peptides AG | Self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids |
| CA3071922A1 (en) | 2017-08-04 | 2019-02-07 | The Governing Council Of The University Of Toronto | Nanoparticle platform for antibody and vaccine delivery |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| IL274130B2 (en) * | 2017-11-01 | 2025-08-01 | Scripps Research Inst | Novel scaffolded hiv-1 vaccine immunogens |
| EP3744847A4 (en) * | 2018-01-22 | 2021-12-08 | Japan as Represented by The Director-General of National Institute of Infectious Diseases | SELECTIVE CD8 POSITIVE T CELL INDUCING VACCINE ANTIGEN |
| US11225502B1 (en) * | 2018-06-11 | 2022-01-18 | Battelle Memorial Institute | Controlled synthesis of hierarchically-structured hybrid materials through peptoid engineering |
| AU2019285048B2 (en) | 2018-06-13 | 2023-06-08 | The Scripps Research Institute | Nanoparticle vaccines with novel structural components |
| US11213582B2 (en) * | 2018-08-08 | 2022-01-04 | The Regents Of The University Of California | Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits |
| RU2713723C1 (ru) * | 2018-11-15 | 2020-02-06 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Искусственные гены, кодирующие белки-иммуногены EV.CTL и EV.Th, рекомбинантные плазмидные ДНК pEV.CTL и pEV.Th, обеспечивающие экспрессию искусственных генов, и искусственные Т-клеточные полиэпитопные белки-иммуногены EV.CTL и EV.Th, содержащие эпитопы антигенов вируса Эбола, используемые для создания вакцины против вируса Эбола |
| AU2020207087A1 (en) | 2019-01-12 | 2021-08-12 | The Methodist Hospital | Self-assembled peptide nanoparticle and use thereof |
| KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| CN112022066A (zh) * | 2020-09-25 | 2020-12-04 | 电子科技大学 | 一种基于深度学习的消化道钩虫发现方法及系统 |
| WO2022106860A1 (en) * | 2020-11-20 | 2022-05-27 | Pécsi Tudományegyetem | Recombinant peptides for use in therapy |
| WO2022149609A1 (ja) * | 2021-01-07 | 2022-07-14 | 国立大学法人東京工業大学 | Mhc分子に適合する病原微生物由来のペプチドが担持された複合蛋白質単量体、当該単量体の会合体、及び当該会合体を有効成分とするコンポーネントワクチン、並びに、免疫後の生理活性物質の分泌に関する情報の取得方法 |
| CN116731209A (zh) * | 2023-06-08 | 2023-09-12 | 中国人民解放军陆军军医大学 | 重组铜绿假单胞菌纳米颗粒蛋白rePO-FN及其应用 |
| WO2025172892A1 (en) | 2024-02-16 | 2025-08-21 | Glaxosmithkline Biologicals Sa | Modified proteins and methods |
| WO2025242657A1 (en) | 2024-05-21 | 2025-11-27 | Shape Biopharmaceuticals Ag | Lipopeptide building blocks and aggregates |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK519188D0 (da) * | 1988-09-16 | 1988-09-16 | Statens Seruminstitut | Kemisk forbindelse |
| CA2037151A1 (en) * | 1990-03-23 | 1991-09-24 | F. Hoffmann-La Roche Ag | Plasmodium sporozoite antigen |
| IL109664A0 (en) * | 1993-05-18 | 1994-08-26 | Rijksuniversiteit | Peptides of human influenza virus for use in human t cell response inducing compositions |
| US6828416B1 (en) * | 1998-08-21 | 2004-12-07 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant multivalent malarial vaccine against Plasmodium falciparum |
| MXPA01005389A (es) * | 1998-11-30 | 2003-03-27 | Cytos Biotechnology Ag | Presentacion molecular ordenada de antigenos, metodos de preparacion y uso. |
| US6756039B1 (en) * | 1999-05-10 | 2004-06-29 | The Regents Of The University Of California | Self assembling proteins |
| EP1191836B1 (en) | 1999-06-25 | 2004-09-29 | Leslie H. Kondejewski | Polypeptide compositions formed using a coiled-coil template and methods of use |
| US6783761B2 (en) * | 2000-05-05 | 2004-08-31 | Aphton Corporation | Chimeric peptide immunogens |
| WO2002100325A2 (en) | 2000-10-13 | 2002-12-19 | Ligocyte Pharmaceuticals, Inc. | Polyvalent nanoparticles |
| AU2002349204A1 (en) | 2001-11-26 | 2003-06-10 | University Health Network | Self-assembling p53 peptides as gene delivery vehicles |
| US8575110B2 (en) * | 2003-02-17 | 2013-11-05 | Alpha-O Peptides G | Peptidic nanoparticles as drug delivery and antigen display systems |
| US7964196B2 (en) | 2004-05-25 | 2011-06-21 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
-
2009
- 2009-01-29 WO PCT/EP2009/050996 patent/WO2009109428A2/en not_active Ceased
- 2009-01-29 JP JP2010544697A patent/JP6088123B2/ja not_active Expired - Fee Related
- 2009-01-29 AU AU2009221419A patent/AU2009221419B2/en not_active Ceased
- 2009-01-29 US US12/864,576 patent/US8546337B2/en active Active
- 2009-01-29 RU RU2010135965/10A patent/RU2540871C2/ru active
- 2009-01-29 CA CA2713879A patent/CA2713879C/en active Active
- 2009-01-29 EP EP09717471A patent/EP2235043A2/en not_active Ceased
- 2009-01-29 CN CN2009801037674A patent/CN101932594A/zh active Pending
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104011065A (zh) * | 2011-08-23 | 2014-08-27 | 哈佛大学校长及研究员协会 | 肽纳米粒子及其用途 |
| CN104011065B (zh) * | 2011-08-23 | 2017-06-30 | 哈佛大学校长及研究员协会 | 肽纳米粒子及其用途 |
| CN104136454A (zh) * | 2011-10-12 | 2014-11-05 | 阿尔法-O肽股份公司 | 作为针对诺如病毒感染的疫苗的自装配肽纳米粒 |
| CN105960412A (zh) * | 2014-01-09 | 2016-09-21 | 阿尔法欧多肽股份公司 | 作为疫苗平台的含鞭毛蛋白的蛋白纳米颗粒 |
| CN105960412B (zh) * | 2014-01-09 | 2021-04-27 | 阿尔法欧多肽股份公司 | 作为疫苗平台的含鞭毛蛋白的蛋白纳米颗粒 |
| CN110290805A (zh) * | 2017-01-03 | 2019-09-27 | 埃默杰克斯疫苗控股有限公司 | 通用流感疫苗组合物 |
| US12605439B2 (en) | 2017-01-03 | 2026-04-21 | Gylden Pharma Limited | Universal influenza vaccine compositions |
| CN110996995A (zh) * | 2017-03-23 | 2020-04-10 | 阿尔法-O肽股份公司 | 具有内置六螺旋束蛋白的自组装蛋白纳米粒子 |
| CN111333733A (zh) * | 2019-04-29 | 2020-06-26 | 中国人民解放军军事科学院军事医学研究院 | 一种可自组装为蛋白纳米颗粒的融合蛋白及其应用 |
| WO2020220846A1 (zh) * | 2019-04-29 | 2020-11-05 | 中国人民解放军军事科学院军事医学研究院 | 一种可自组装为蛋白纳米颗粒的融合蛋白及其应用 |
| CN111333733B (zh) * | 2019-04-29 | 2022-05-03 | 中国人民解放军军事科学院军事医学研究院 | 一种可自组装为蛋白纳米颗粒的融合蛋白及其应用 |
| CN111150842A (zh) * | 2019-12-31 | 2020-05-15 | 优锐生物医药科技(深圳)有限公司 | 一种用于中和胃泌素的主动免疫调控微粒及其制备方法和应用 |
| CN111150841B (zh) * | 2019-12-31 | 2023-08-15 | 优锐生物医药科技(深圳)有限公司 | 一种主动免疫调控微粒及其制备方法和应用 |
| CN111150842B (zh) * | 2019-12-31 | 2023-09-05 | 优锐生物医药科技(深圳)有限公司 | 一种用于中和胃泌素的主动免疫调控微粒及其制备方法和应用 |
| CN111150841A (zh) * | 2019-12-31 | 2020-05-15 | 优锐生物医药科技(深圳)有限公司 | 一种主动免疫调控微粒及其制备方法和应用 |
| CN119060144A (zh) * | 2024-10-31 | 2024-12-03 | 南京澄实生物医药科技有限公司 | 一种预防犬瘟热病毒感染的融合蛋白和疫苗及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009109428A3 (en) | 2010-04-01 |
| CA2713879C (en) | 2020-01-07 |
| RU2010135965A (ru) | 2012-03-10 |
| AU2009221419A1 (en) | 2009-09-11 |
| AU2009221419B2 (en) | 2013-09-26 |
| US20110020378A1 (en) | 2011-01-27 |
| US8546337B2 (en) | 2013-10-01 |
| EP2235043A2 (en) | 2010-10-06 |
| JP2011511773A (ja) | 2011-04-14 |
| CA2713879A1 (en) | 2009-09-11 |
| RU2540871C2 (ru) | 2015-02-10 |
| WO2009109428A2 (en) | 2009-09-11 |
| JP6088123B2 (ja) | 2017-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009221419B2 (en) | Self-assembling peptide nanoparticles useful as vaccines | |
| US11324836B2 (en) | Modified virus-like particles of CMV | |
| DK2547364T3 (en) | Peptides, conjugates and methods for increasing the immunogenicity of a vaccine | |
| AU2012204955B2 (en) | Monomeric and multimeric immunogenic peptides | |
| Monso et al. | Influence of conjugation chemistry and B epitope orientation on the immune response of branched peptide antigens | |
| CN101141979A (zh) | 猫变应原融合蛋白及其用途 | |
| US10501499B2 (en) | Peptides derived from viral proteins for use as immunogens and dosage reactants | |
| CN101848730B (zh) | 衣壳蛋白及其用途 | |
| US20140242104A1 (en) | Self-assembling peptide nanoparticles as vaccines against infection with norovirus | |
| CN102946901A (zh) | 模板化成双链卷曲螺旋的呼吸病毒表位及其在免疫中的应用 | |
| RU2358981C2 (ru) | Универсальная вакцина против вируса гриппа птиц | |
| Bárcena et al. | Design of novel vaccines based on virus-like particles | |
| EP2012829A2 (en) | Method for producing viral vaccine and therapeutic peptide antigens | |
| JP2024502823A (ja) | 安定なコロナウィルスタンパク質およびそのワクチン組成物 | |
| HK1152533A (en) | Self-assembling peptide nanoparticles useful as vaccines | |
| US11535651B2 (en) | Hepatitis B nanoparticle-based vaccine for influenza virus | |
| CN115916237A (zh) | 抗病毒病原体的疫苗 | |
| HK40077650B (zh) | Cmv的修饰病毒样颗粒 | |
| Yan et al. | Strategies for designing peptide immunogens to elicit α-helical conformation-specific antibodies reactive with native proteins | |
| BR112017008266B1 (pt) | Partícula semelhante a vírus (vlp) modificada do vírus do mosaico do pepino (cmv) e composição farmacêutica | |
| JP2014508144A (ja) | 免疫応答を刺激するためのプラットフォーム技術を利用するコンジュゲート | |
| BR122024008858A2 (pt) | Uso de uma partícula semelhante a vírus (vlp) modificada do vírus do mosaico do pepino (cmv), ou uma composição compreendendo a referida partícula no tratamento de uma doença, distúrbio ou condição em um animal ou ser humano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1152533 Country of ref document: HK |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20101229 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1152533 Country of ref document: HK |